Search research articles
Contact Us
Filters
Showing results (11-20 of 112) with videos related to
Page
of 12
Sort By:
Oral Oncology
|
December 7, 2007
Nasopharyngeal carcinoma: current management, future directions and dental implications
Mark Agulnik, Joel B Epstein
Cancer
|
June 7, 2022
Evolving strategies for management of desmoid tumor
Richard F Riedel, Mark Agulnik
Drugs
|
August 7, 2008
Promising newer molecular-targeted therapies in head and neck cancer
Lili X Wang, Mark Agulnik
Hematology/Oncology Clinics of North America
|
November 23, 2006
The changing management of low-grade astrocytomas and oligodendrogliomas
Mark Agulnik, Warren P Mason
Current Neurology and Neuroscience Reports
|
April 26, 2006
Recent advances in the treatment of oligodendrogliomas
Mark Agulnik, Warren P Mason
Seminars in Oncology
|
June 12, 2008
Salivary gland malignancies: the role for chemotherapy and molecular targeted agents
Sujani G Surakanti, Mark Agulnik
American Journal of Clinical Oncology
|
July 10, 2012
Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor
Mark Agulnik, Jennifer L Giel
Expert Opinion on Pharmacotherapy
|
March 1, 2006
Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA
Mark Agulnik, Lillian L Siu
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 12, 2008
The role of inhibitors of the epidermal growth factor in management of head and neck cancer
Bruce Brockstein, Mario Lacouture, Mark Agulnik
Oncology (Williston Park, N.Y.)
|
December 9, 2010
Head and neck cancer: changing epidemiology and public health implications
Leslie Kim, Tiffany King, Mark Agulnik
Page
of 12
Search research articles
Search
Showing results (11-20 of 112) with videos related to
Sort By:
Page
of 12
Oral Oncology
|
December 7, 2007
Nasopharyngeal carcinoma: current management, future directions and dental implications
Mark Agulnik, Joel B Epstein
Cancer
|
June 7, 2022
Evolving strategies for management of desmoid tumor
Richard F Riedel, Mark Agulnik
Drugs
|
August 7, 2008
Promising newer molecular-targeted therapies in head and neck cancer
Lili X Wang, Mark Agulnik
Hematology/Oncology Clinics of North America
|
November 23, 2006
The changing management of low-grade astrocytomas and oligodendrogliomas
Mark Agulnik, Warren P Mason
Current Neurology and Neuroscience Reports
|
April 26, 2006
Recent advances in the treatment of oligodendrogliomas
Mark Agulnik, Warren P Mason
Seminars in Oncology
|
June 12, 2008
Salivary gland malignancies: the role for chemotherapy and molecular targeted agents
Sujani G Surakanti, Mark Agulnik
American Journal of Clinical Oncology
|
July 10, 2012
Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor
Mark Agulnik, Jennifer L Giel
Expert Opinion on Pharmacotherapy
|
March 1, 2006
Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA
Mark Agulnik, Lillian L Siu
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 12, 2008
The role of inhibitors of the epidermal growth factor in management of head and neck cancer
Bruce Brockstein, Mario Lacouture, Mark Agulnik
Oncology (Williston Park, N.Y.)
|
December 9, 2010
Head and neck cancer: changing epidemiology and public health implications
Leslie Kim, Tiffany King, Mark Agulnik
Page
of 12